학술논문
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
Document Type
Article
Author
O’Brien, Mary ; Paz-Ares, Luis ; Marreaud, Sandrine; Dafni, Urania; Oselin, Kersti; Havel, Libor; Esteban, Emilio; Isla, Dolores; Martinez-Marti, Alex; Faehling, Martin; Tsuboi, Masahiro; Lee, Jong-Seok; Nakagawa, Kazuhiko; Yang, Jing; Samkari, Ayman; Keller, Steven M; Mauer, Murielle; Jha, Nitish; Stahel, Rolf; Besse, Benjamin ; Peters, Solange
Source
In The Lancet Oncology October 2022 23(10):1274-1286
Subject
Language
ISSN
1470-2045